NR3C2 and chronic kidney disease: However, blockade of central AT1a by intracerebroventricular administration of AT1a antagonist losartan, at a dose of 0.2% of the effective intragastric dose, inhibited the overexpression of RAS.20 Similarly, since central effects of mineralocorticoid receptor (MR) activation are mediated via stimulation of angiotensinergic sympathoexcitatory pathways,51,52 central MR blockade might be of therapeutic benefit for patients with CKD and HF.